Leerink Partnrs Has Negative Forecast for MREO Q4 Earnings

Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) – Equities research analysts at Leerink Partnrs reduced their Q4 2025 earnings per share (EPS) estimates for shares of Mereo BioPharma Group in a report issued on Monday, November 10th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of $0.04 per share for the quarter, down from their previous estimate of $0.05. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share.

Mereo BioPharma Group (NASDAQ:MREO) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $0.30 million for the quarter, compared to analyst estimates of $3.70 million.

Several other equities research analysts have also recently weighed in on MREO. Wall Street Zen raised Mereo BioPharma Group from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Zacks Research cut shares of Mereo BioPharma Group from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 14th. JPMorgan Chase & Co. raised their price target on shares of Mereo BioPharma Group from $7.00 to $8.00 and gave the stock an “overweight” rating in a research report on Monday, August 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Mereo BioPharma Group in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.40.

Mereo BioPharma Group Stock Performance

Shares of NASDAQ:MREO opened at $1.87 on Wednesday. The stock’s 50-day moving average is $1.91 and its 200-day moving average is $2.10. The company has a market cap of $297.33 million, a P/E ratio of -31.17 and a beta of 0.41. Mereo BioPharma Group has a 52-week low of $1.47 and a 52-week high of $4.29.

Hedge Funds Weigh In On Mereo BioPharma Group

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Marex Group plc bought a new stake in Mereo BioPharma Group in the second quarter valued at $27,000. State of New Jersey Common Pension Fund D bought a new stake in shares of Mereo BioPharma Group in the 3rd quarter worth about $32,000. Significant Wealth Partners LLC increased its position in shares of Mereo BioPharma Group by 61.7% during the 2nd quarter. Significant Wealth Partners LLC now owns 22,261 shares of the company’s stock worth $60,000 after purchasing an additional 8,490 shares in the last quarter. Forefront Wealth Partners LLC bought a new position in Mereo BioPharma Group during the 3rd quarter valued at about $68,000. Finally, Avanza Fonder AB boosted its position in Mereo BioPharma Group by 36.0% in the second quarter. Avanza Fonder AB now owns 38,235 shares of the company’s stock valued at $104,000 after buying an additional 10,114 shares in the last quarter. Institutional investors own 62.83% of the company’s stock.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.